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ABSTRACT
Objective To quantify the risk and severity of negative
effects of treatment for localised prostate cancer on long
term quality of life.
Design Population based, prospective cohort study with
follow-up over three years.
Setting New South Wales, Australia.
Participants Men with localised prostate cancer were
eligible if aged less than 70 years, diagnosed between
October 2000 and October 2002, and notified to the New
South Wales central cancer registry. Controls were
randomly selected from the New South Wales electoral
roll and matched to cases by age and postcode.
Main outcome measures General health specific and
disease specific function up to three years after
diagnosis, according to the 12 item short form health
survey and the University of California, Los Angeles
prostate cancer index.
Results 1642 (64%) cases and 495 (63%) eligible and
contacted controls took part in the study. After
adjustment for confounders, all active treatment groups
had low odds of having better sexual function than
controls, in particular men on androgen deprivation
therapy (adjusted odds ratio (OR) 0.02, 95% CI 0.01 to
0.07). Men treated surgically reported the worst urinary
function (adjusted OR 0.17, 95% CI 0.13 to 0.22). Bowel
function was poorest in cases who had external beam
radiotherapy (adjusted OR 0.44, 95% CI 0.30 to 0.64).
General physical and mental health scores were similar
across treatment groups, but poorest in men who had
androgen deprivation therapy.
ConclusionsThevarioustreatmentsforlocalisedprostate
cancer each have persistent effects on quality of life.
Sexual dysfunction three years after diagnosis was
common in all treatment groups, whereas poor urinary
function was less common. Bowel function was most
compromised in those who had external beam
radiotherapy.Menwithprostatecancerandtheclinicians
who treat them should be aware of the effects of
treatment on quality of life, and weigh them up against
the patient’s age and the risk of progression of prostate
cancer if untreated to make informed decisions about
treatment.
INTRODUCTION
Survival after diagnosis of prostate cancer has
increased substantially in the past two decades. Five
year relative survival for localised prostate cancer is
almost 100% in Australia
1 and the United States.
2
Observational studies show that different treatment
options offer nearly equal survival rates
3; therefore,
qualityoflifeaftertreatmentshouldbeamajorconsid-
eration in treatment decision making. Dissatisfaction
with care in some men may be owing, in part, to a
lack of accurate and representative information on
the long term effects of treatment.
4
The primary aims of the New South Wales Prostate
Cancer Care and Outcomes Study (PCOS) were to
documentthecaregiventomenwithnewlydiagnosed
prostatecancerandtomeasurethreeyearandfiveyear
health related quality of life.
METHODS
Study population
Allmenagedlessthan70years,residentinNewSouth
Wales, diagnosed with histopathologically confirmed
prostate cancer—that is, clinical stage T1a to T2c with
no evidence of lymph node or distant metastases—
betweenOctober2000andOctober2002,andnotified
to the population based New South Wales central can-
cer registry by May 2003 or no more than 12 months
after their diagnosis, were eligible for this study. We
enrolled only men aged less than 70 years at diagnosis
because radical treatment is generally not offered to
men with less than 10 years life expectancy.
5 Of all
the Australian men diagnosed with prostate cancer
during the study period, 45% were aged less than
70 years.
6 Pathology companies, hospitals, radio-
therapy centres, day therapy centres, and the registrar
of births, deaths, and marriages are legally required to
notify all cancer cases to the cancer registry.
1 Rapid
ascertainment procedures were implemented by the
central cancer registry to minimise the time between
diagnosis and recruitment for the study.
Patient participation was sought as soon as possible
afterthecentralcancerregistryreceivednotificationof
a case, but not less than one month after diagnosis.
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to approachtheirrecentlydiagnosedpatients.Doctors
were alsoaskedtoconfirmthateach patientwasaware
ofhisdiagnosisandphysicallyandmentallycapableof
a 30 minute telephone interview in English. A total of
254doctorswerecontactedregardingtheparticipation
of 3195 men. Eight doctors, managing the care of 336
patients, refused any approach to their patients. A
further 246 doctors denied on an individual basis con-
sent to approach an additional 152 potentially eligible
patients, and doctor’s consent was still pending at the
close of the study for 49 men. Permission was granted
toapproach2658patients(83% ofthosenotifiedtothe
central cancer registry). Of those approached, 2031
agreed to take part in the study (63.6% of those identi-
fied and 76.4% of those approached; fig 1).
A total of 1347 potential controls, matched by age
and postcode of residence to cases, were randomly
selected from the New South Wales electoral roll.
The intention was to enrol 500 matched controls into
the study. Potential controls were first checked against
thecentralcancerregistrytoexcludethosewithadiag-
nosis of prostate cancer, then cross referenced using
telephone directory listings to identify those with a
listed telephone number. In total, 947 men with direc-
tory listings were sent an invitation letter. A follow-up
phonecallwasmadeaftertwoweekstoobtainthecon-
sent of invited controls and to book a telephone inter-
view. Of those contacted, 281 men refused to
participate and 41 were found to be ineligible because
they could not complete a 30 minute telephone inter-
view in English or were not residents of New South
Wales. In addition, 118 potential controls could not
be contacted. A total of 507 men agreed to participate
and495completedabaselineinterview(62.8%ofmen
contacted and eligible).
Data collection
Clinical data for men diagnosed with prostate cancer
Atrainedfieldworkerorthetreatingdoctorcompleted
adatacollectionformforeachparticipantwithprostate
cancer.Dataonclinicalstageatdiagnosisandmanage-
ment during the first year after diagnosis were
obtained. Data were collected no sooner than
12monthsafterdiagnosisinordertoobtainacomplete
description of treatment during the first year.
Initial primary treatment was defined as the treat-
ment given within six months of diagnosis. Treatment
was classified into one of the following categories:
active surveillance, radical prostatectomy, external
beam radiotherapy, androgen deprivation therapy,
low dose rate brachytherapy, high dose rate brachy-
therapy, or any combination of these. If a man was
first recommended to have active surveillance but
had active treatment within six months of diagnosis,
he was coded as having had active treatment.
Clinical data were obtained for 1874 men (94% of
the sample). A total of 80 men (4%) who gave tele-
phone interviews did not consent to collection of clin-
icalinformation;accesstoclinicalnotesforafurther41
men(2%)couldnotbeobtained.Ofthe1874menwith
clinical information, 1642 had localised disease and
were included in this analysis (fig 1).
Twofieldworkerscollecteddataindependentlyona
random subsample of 60 cases from five doctors. Fair
to very good agreement between field workers was
observed for the following key variables: prostate spe-
cific antigen level at diagnosis (90% agreement); Glea-
son score (70% agreement, Cohen’s kappa score for
inter-rater agreement κ=0.56); tumour stage (80%
agreement, κ=0.62), and type of initial primary treat-
ment (100% agreement, κ=1). In two thirds of cases
whereGleasonscoresdisagreed,areportonpathology
of a repeat biopsyor a prostatectomy sample that gave
adifferentscoretotheoriginalbiopsyreportwasavail-
able to the second field worker.
Self reported health related measures for cases and controls
Trained interviewers interviewed each case and con-
trol using a computer assisted telephone interview.
Validated measures were included, with some minor
wording changesto suit the Australiancontext and tel-
ephone administration. The final survey instrument is
available from the authors on request.
Potentially eligible cases (n=3195)
Patients for whom doctor gave consent to contact (n=2658)
Patients who gave consent (n=2031)
Doctor did not consent (n=537):
  Doctor refused all participation (n=336 patients under
    eight doctors)
  Doctor refused consent (n=152 patients from 246
    doctors)
  Consent from doctor pending at study close (n=49
    patients)
Refused consent (n=627)
Patients assessed at baseline (n= 1995)
Withdrew or lost to follow up before baseline (n=36)
Patients with localised prostate cancer (n=1642)
Advanced stage cancer (n= 232)
Patients interviewed at one year (n=1599)
Lost to follow-up (n=43)
Patients interviewed at two years (n=1530)
Lost to follow-up (n=69)
Patients interviewed at three years (n=1493)
Lost to follow-up (n=37)
Patients for whom clinical records were obtained (n=1874)
Cancer stage unknown (n=121):
  Patient refused access to medical notes (n=80)
  Medical notes could not be found (n=41)
Fig 1 | Flow diagram showing case participation and follow-up
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Health related quality of life was measured using the
domain specific items of the long form University of
California, Los Angeles prostate cancer index.
7 This
is a well validated instrument suitable for both cases
and controls and has good reliability for recall of
prediagnosis symptoms when administered within six
months of diagnosis.
8 The University of California,
Los Angeles prostate cancer index contains all items
in the 12 item short form (SF-12) health status instru-
ment. SF-12 has excellent reliability and validity.
9
The University of California, Los Angeles prostate
cancer index also includes 20 items that measure the
domains of urinary, bowel, and sexual function, yield-
ing three function scales; higher scores indicate better
function. In addition, the index includes a single item
measure of “bother” for each domain (“what was the
level of bother for (urinary/bowel/sexual) function?”);
higherscoresindicatelessbother.Thesesixscalesplus
the physical component score and the mental compo-
nent score from the SF-12 comprised the eight quality
of life outcomes used in this study.
Other health related measures
The international prostate symptom score
10 was used
at baseline to measure obstructive or irritative urinary
problems. Participants were also asked about 12
chronic comorbid conditions. A total comorbidity
scorewas calculatedforeach man, withone pointcon-
tributed by each of the following conditions that lim-
ited their activity or required prescription medicine:
cerebrovascular disease; inflammatory bowel disease;
liver disease; gastric ulcers; arthritis; diabetes; depres-
sion; hypertension; chest pain; heart attack; heart fail-
ure; and chronic lung disease. Questions were also
asked on tobacco use and alcohol intake.
Timing of interviews
For cases, “baseline” was defined as the month before
diagnosis;however,datawerecollectedafterdiagnosis
in all cases because of the observational study design.
The baseline interviews for cases were done as soon as
practicable after recruitment (mean 3 months after
diagnosis (range one to 12 months)) and, in the major-
ityofcases,occurredafterprimarytherapyhadbegun.
Four cases who did not complete a baseline interview
but completed later interviews were excluded from
analysis because baseline outcome was a necessary
covariate. We excluded 205 men who were diagnosed
more than 12 months before the date of identification
to reduce the likelihood of error in self reported base-
line health status. Controls were asked to recall their
baseline health status three months before the date of
interview; this approach was used to standardise the
recall time for cases and controls and to minimise dif-
ferential recall bias.
Follow-up interviews were scheduled one, two, and
three years after diagnosis for cases and one, two, and
fiveyearsafterbaselineinterviewforcontrols.Asmost
treatmentscarry short term adverse effects we concen-
tratedonoutcomesatthreeyearsafterdiagnosis,when
effects on quality of life would generally have
stabilised.
11 To reduce both costs and responder fati-
gue, the three year assessment in controls was omitted
and values were estimated on the basis of outcomes at
five years. A total of 380 (79%) controls completed an
interviewatfiveyears;however,22controlswerediag-
nosedwithprostatecancerduringthestudyperiodand
were censored from the analysis at the time of their
diagnosis. The majority (93%) of interviews were con-
ductedwithinonemonth(±4weeks)oftheanniversary
of diagnosis (cases) or baseline interview (controls).
Data analysis
Data were analysed with SPSS and STATA software.
The physical component scores and mental compo-
nent scores were calculated according to the user
manual
12 and on the basis of Australian population
norms
13 and scoring weights. Scores were normalised
toapopulationmeanof50and astandarddeviationof
10. Higher scores reflect better quality of life.
Scores for the six disease specific domains were cal-
culated according to the instructions for the prostate
cancer index
14 and ranged from 0 to 100, with higher
scores indicating better function or less bother. The
scores for each domain were divided into ordinal cate-
gories because of their asymmetric distributions. Pro-
portional odds ordinal logistic regression models were
fitted for each domain and treatment group, with the
controls used as the reference group. Cluster robust
variance estimators and independence working corre-
lation matrices were used to provide unbiased esti-
mated standard errors in the presence of correlation
between repeated observations on the same subjects.
Domain scores were grouped into three to five cate-
gories to provide a relatively even balance of observa-
tions in each category.
Ourprimaryinterestwasintheeffectoftreatmentat
yearly intervals up to three years after baseline, so the
interaction between treatment type and time was
examined. Treatment comparisons at three years
were complicated by the fact that data were not col-
lected for controls at this time point. However, we
modelled the case and control log odds trajectories as
linear from year two onwards by using control group
responses measured at five years after baseline, so that
themodeleffectivelyinterpolatedtreatmentgroupand
control comparisons at year three. Furthermore, the
log odds trajectory from years one to two for a given
treatment group was allowed to differ from the subse-
quent log odds trajectory for that treatment group
through the inclusion of an additional segmented
regression parameter.
All demographic and clinical variables were consid-
ered as potential confounders for quality of life and
wereincludedinthemultivariablemodels.Acommon
model selection process was used for each of the eight
quality of life outcomes. First, a “full model” was fitted
to the data using the categorised quality of life score as
the dependent variable. For each domain, the baseline
quality of life score was treated as a continuous covari-
ateandwasincludedinthe“fullmodel,”alongwiththe
RESEARCH
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afterbaselinemeasurement(one,two,andthreeyears);
age (<55, 55-59, 60-64, and 65-69 years); and all other
demographic and clinical variables except tumour
stage,Gleasonscore,andprostatespecificantigencon-
centration (all of which were very strongly correlated
with treatment type (data not shown)).
A “reduced model” was then derived from the full
model. We adjusted for the confounders that were sig-
nificantly associated with treatment group outcomes
(P>0.05) or changed their odds ratios by 10% or
more when included in the model. Baseline score,
time after baseline, treatment group, and age were all
retained in the reduced model. The proportional odds
assumption was checked for each “reduced model”
and if not met (as was the case for three of the eight
domains),additionalanalysisincludingpartialpropor-
tional odds models was used to assess the effect of the
violation. Following this approach had little effect on
theconclusions,andthusresultsfromtheproportional
odds models are reported for ease of interpretation.
Generalised estimating equations for longitudinal
binary outcomes were used to examine the potential
influenceofmissingdata.Foreachoftheeightdomains,
a binaryindicatorofoutcome measurement attainment
at time t (0=missing, 1=attained) was regressed on the
most recent outcome value before time t and all signifi-
cant covariates from the corresponding “reduced
model.”Althoughtheseanalysesidentifiedthatmissing
datawassometimesassociatedwithcovariatesincluded
in the corresponding “reduced model,” there was little
evidencethatthiswasindependentlyassociatedwiththe
most recent previous outcome value (P values ranged
from 0.14 to 0.98).
RESULTS
The 1642 men with localised prostate cancer included
in this study were 37 to 69 years of age (mean 61.
2 years) when diagnosed (table 1). A total of 981 cases
(60%) had radical prostatectomy, and most of the
remainder had external beam radiotherapy, with or
without androgen deprivation therapy (289/1636
(18%)) or active surveillance (200/1636 (12%)). Just
over half of the radical prostatectomies were nerve
sparing in intent (494/981). Four men who had orchi-
dectomy as primary therapy and two with unknown
primary therapy were excluded from further analysis.
There was significant heterogeneity within treat-
ment types of all demographic characteristics—except
country of birth and comorbidity—and all disease
characteristics (all P<0.001). Cases who had radical
prostatectomy or low dose rate brachytherapy tended
to be younger and have earlier stage disease, lower
prostate specific antigen levels, and lower Gleason
scorethan casesin other treatmentgroups, and tended
to have higher incomes and better education. Cases
who had nerve sparing prostatectomy were younger
andmorelikelytohavehigherbaselinesexualfunction
thanthosewhodidnothaveit.Caseswhohadexternal
beam radiotherapy or androgen deprivation therapy,
or the two combined, were older, had later stage
disease, and had more comorbidity than those who
received other treatments. There were no substantial
differences in the demographic profiles of the controls
and the cases (pooled across treatments).
A total of 1493 (91%) patients with prostate cancer
interviewed at baseline were also interviewed at three
years; 1530 (93%) cases and 433 (87%) controls com-
pleted the two year interview. Completion rates dif-
fered across treatment groups and ranged from 97%
(lowdoseratebrachytherapy)to77%(androgendepri-
vation therapy (fig 2). The smallest number of cases
remaining at three years in any group was 43 in the
group who had been treated with high dose rate
brachytherapy. When all variables in table 1 were
included in a logistic regression model, only being
born overseas (odds ratio (OR) 1.52, 95% confidence
interval(CI)1.02to2.27)andnothavingprivatehealth
insurance(OR1.85,95%CI1.21to2.83)increasedthe
likelihood of withdrawal from the study.
At thethreeyearinterview,99 cases(6.6%)reported
that they had been diagnosed with “recurrent disease
ordiseasethathadspreadafterdiagnosis.”Noneofthe
men who had received low dose rate brachytherapy
reported this outcome, whereas two (2%) who had
undergone external beam radiotherapy, five (3%) on
active surveillance, 64 (7%) who had been treated
with radical prostatectomy, and four (30%) who had
receivedandrogendeprivationtherapyalonereported
recurrent disease or disease spread. Of the variables in
table 1, only Gleason score (OR 1.87, 95% CI 1.47 to
2.38) and the log of prostate specific antigen level (OR
1.96, 95% CI 1.42 to 2.72) were independent, statisti-
cally significant predictors of recurrence or spread.
General quality of life
Table2presentsthemeanscoresforeachqualityoflife
domain and treatment group at baseline and at year
three. Given that these scores are not adjusted for clin-
ical and demographic characteristics, they reflect the
combined impact of disease, treatment, and age on
long term quality of life. Mental component scores of
casesatbaselineweresimilartothoseofcontrolsforall
groups, except those having non-nerve sparing radical
prostatectomy (table 2). Overall, men with localised
prostate cancer had higher baseline physical scores
thancontrols,inparticularmenwhohadnervesparing
radical prostatectomy (OR 1.85, 95% CI 1.48 to 2.32)
orlowdoseratebrachytherapy(OR2.36,95%CI1.43
to 3.89). Men who had androgen deprivation therapy,
however, had lower scores than controls.
After adjustment for baseline physical component
score,age,income,areaofresidence,andcomorbidity,
men who had androgen deprivation therapy alone
were least likely to have better physical scores than
controls at three years after diagnosis (fig 3).
Cases who had radical prostatectomy or high dose
rate brachytherapy were unlikely to have a higher
mental component score than controls in the first
year (fig 3). However, mental component scores for
cases in all treatments groups were similar to those of
controls at three years.
RESEARCH
page 4 of 12 BMJ | ONLINE FIRST | bmj.comUrinary function and bother
At baseline, few cases (33/1636 (2.0%)) reported urin-
ary incontinence—that is, few agreed that they experi-
enced“urinaryleakagethatrequiredoneormorepads
per day to control.” This single measure of inconti-
nence, which does not include all forms of inconti-
nence, was most prevalent at baseline in men who
subsequently had androgen deprivation therapy
(4/61 (6.6%)) or active surveillance (12/200 (6.0%);
table 3). After diagnosis, the highest rate of inconti-
nencewasinthegroupwhohadradicalprostatectomy:
156 men (16.3%) reported incontinence at one year
and 111 (12.3%) at three years.
All men except those who had undergone nerve
sparingradicalprostatectomyorlowdoseratebrachy-
therapy had lower urinary function scores than con-
trols at baseline (table 2). Urinary function scores fell
significantly below control scores in all groups
between baseline and year one, except for in cases on
active surveillance, androgen deprivation therapy, or
high dose rate brachytherapy (fig 4). The odds ratio
was lowest in those who had radical prostatectomy
(OR 0.17, 95% CI 0.13 to 0.22). For all groups except
those on androgen deprivation therapy or high dose
rate brachytherapy, the adjusted odds ratio increased
orstabilisedbetweenyearoneandyearthree.Alltreat-
mentgroupshadworseurinarybotheratbaselinethan
did controls (table 2), and this persisted up to three
years in most groups (fig 4).
Urinarybotheratbaselineinallmenwashighlycor-
relatedwiththeirinternationalprostatesymptomscore
(R
2=0.56; P<0.001), more so than with the University
of California, Los Angeles prostate cancer index urin-
aryfunctionscore(R
2=0.21;P<0.001).Ofthemenwho
reported less urinary bother than controls three years
after diagnosis, 68 men (64%) on active surveillance
and 22 men (34%) on androgen deprivation therapy
had a transurethral resection of the prostate. The fact
Table 1 |Baseline demographic and clinical characteristics of cases of prostate cancer and baseline demographic characteristics of controls
Treatment group (n (%)) Overall (n (%))
P value for
heterogeneity
amonggroups
Active
surveillance
(n=200)
Radical
prostatectomy
(n=981)
EBRT
(n=123)
ADT
(n=61)
Combined
EBRT/ADT
(n=166)
LDR
brachytherapy
(n=58)
HDR
brachytherapy
(n=47)
Cases
(n=1636)
Controls
(n=495)
Age at diagnosis (years)
<55 20 (10.0) 163 (16.6) 5 (4.1) 4 (6.6) 13 (7.8) 8 (13.8) 4 (8.5) 217 (13.3) 82 (16.6) <0.001
55-59 38 (19.0) 273 (27.8) 13 (10.6) 8 (13.1) 19 (11.4) 18 (31.0) 13 (27.7) 382 (23.3) 68 (13.7)
60-64 54 (27.0) 275 (28.0) 35 (28.5) 14 (23.0) 52 (31.3) 17 (29.3) 12 (25.5) 459 (28.1) 142 (28.7)
65-69 88 (44.0) 270 (27.5) 70 (56.9) 35 (57.4) 82 (49.4) 15 (25.9) 18 (38.3) 578 (35.3) 203 (41.0)
Mean (95% CI) 65.8
(62.5 to 69)
60.2
(59.9 to 60.6)
63.9
(63 to 64.7)
64.0
(62.8 to 65.2)
63.3
(62.5 to 64)
60.0
(58.6 to 61.4)
62.2
(60.7 to 63.6)
61.2
(61 to 61.5)
61.2
(60.7 to 61.7)
Private health insurance status
Insured 131 (65.5) 755 (77.1) 55 (44.7) 25 (41.7) 84 (50.6) 49 (84.5) 43 (91.5) 1142 (68.4) 312 (63.3) <0.001
Uninsured 69 (34.5) 224 (22.9) 68 (55.3) 35 (58.3) 82 (49.4) 9 (15.5) 4 (8.5) 491 (31.6) 181 (36.7)
Comorbidity score
0 62 (31.0) 427 (43.5) 33 (26.8) 13 (21.3) 46 (27.7) 24 (41.4) 18 (38.3) 623 (37.9) 184 (37.2) <0.001
1 59 (29.5) 311 (31.7) 39 (31.7) 22 (36.1) 64 (38.6) 20 (34.5) 14 (29.8) 529 (32.1) 154 (31.1)
2+ 79 (39.5) 243 (24.8) 51 (41.5) 26 (42.6) 56 (33.7) 14 (24.1) 15 (31.9) 484 (30.1) 157 (31.7)
Clinical stage at diagnosis
T1a 58 (29.0) 4 (0.4) 1 (0.8) 1 (1.6) 1 (0.6) 0 (0.0) 0 (0.0) 65 (4.0) n/a <0.001
T1b 19 (9.5) 15 (1.5) 4 (3.3) 5 (8.2) 2 (1.2) 0 (0.0) 1 (2.1) 46 (2.8) n/a
T1c 83 (41.5) 516 (52.6) 56 (45.5) 16 (26.2) 51 (30.7) 43 (74.1) 13 (27.7) 778 (47.6) n/a
T2a 26 (13.0) 239 (24.4) 31 (25.2) 9 (14.8) 33 (19.9) 12 (20.7) 10 (21.3) 360 (22.0) n/a
T2b 6 (3.0) 120 (12.2) 19 (15.4) 10 (16.4) 55 (33.1) 2 (3.4) 18 (38.3) 230 (14.1) n/a
T2c 8 (4.0) 87 (8.9) 12 (9.8) 20 (32.8) 24 (14.5) 1 (1.7) 5 (10.6) 157 (9.6) n/a
Gleason score
2 to 6 172 (89.1) 539 (55.1) 57 (47.1) 9 (14.8) 49 (29.5) 53 (91.4) 15 (31.9) 894 (55.0) n/a <0.001
7 19 (9.8) 356 (36.4) 55 (45.5) 26 (42.6) 71 (42.8) 5 (8.6) 25 (53.2) 557 (34.3) n/a
8 to 10 2 (1.0) 83 (8.5) 9 (7.4) 26 (42.6) 46 (27.7) 0 (0.0) 7 (14.9) 173 (10.7) n/a
Mean (95% CI) 5.6(5.5to5.8) 6.5 (6.4 to 6.5) 6.5(6.4to6.7) 7.4(7.1to7.7) 7.1(6.9to7.2) 6.0 (5.9 to 6.1) 6.9 (6.6 to 7.1) 6.5(6.4to6.5) n/a
PSA at diagnosis
<4 59 (32.4) 77 (8.0) 8 (6.5) 2 (3.4) 2 (1.2) 2 (3.4) 2 (4.3) 152 (9.5) n/a <0.001
4 to 9.9 93 (51.1) 643 (66.8) 67 (54.5) 5 (8.5) 48 (29.1) 46 (79.3) 18 (38.3) 920 (57.6) n/a
10 to 19.9 22 (12.1) 195 (20.2) 38 (30.9) 13 (22.0) 51 (30.9) 8 (13.8) 17 (36.2) 344 (21.5) n/a
20+ 8 (4.4) 48 (5.0) 10 (8.1) 39 (66.1) 64 (38.8) 2 (3.4) 10 (21.3) 181 (11.3) n/a
Median (range) 5.7
(0.3 to 41.5)
7.2
(0.3 to 602)
8.2
(0.2 to 45)
28.2
(1.5 to 250.9)
14.6
(2.7 to 190)
7.2
(2.1 to 23.3)
10.5
(2.5 to 75.9)
7.7
(0.2 to 602)
n/a
Abbreviations: ADT, androgen deprivation therapy; EBRT, external beam radiotherapy; HDR, high dose rate brachytherapy; LDR low dose rate brachytherapy; PSA, prostate specific antigen.
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explain the reduction in bother.
Bowel function and bother
Bowel problems were defined as responding to the
question “Overall, how big a problem have your
bowel habits been?” with either “moderate” or “big.”
Although bowel function of cases at baseline was gen-
erallysimilartothatofcontrols(table2),menwhohad
external beam radiotherapy, both with and without
androgen deprivation therapy, had worse bowel func-
tionthancontrolsatoneyear(OR0.51,95%CI0.34to
0.74)andatthreeyears(OR0.58,95%CI0.39to0.86)
after diagnosis (fig 4). Bowel bother was persistently
worse in all treatment groups relative to controls,
with the greatest impact in the groups who received
treatment that included external beam radiotherapy
either alone at one year (OR 0.24, 95% CI 0.15 to
0.36) and three years (OR 0.22, 95% CI 0.14 to 0.34)
or in combination with androgen deprivation therapy
at one year (OR 0.24, 95% CI 0.16 to 0.35) and three
years (OR 0.19 95% CI 0.13 to 0.28).
Sexual function and bother
Sexual function at baseline differed between groups
(tables 2 and 3)—15.6% (76/494) of men who
subsequently had nerve sparing radical prostatectomy
were impotent at baseline compared with 42.1%
(24/61) of those who had androgen deprivation ther-
apy. On the other hand, 109 controls (22.3%) and 128
men (27.6%) who had non-nerve sparing radical pros-
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Fig 2 | Percentage of quality of life interviews completed
annually by each group. Abbreviations: ADT, androgen
deprivation therapy; EBRT, external beam radiation therapy;
HDR, high dose rate; LDR, low dose rate
Table 2 |Mean unadjusted physical, mental, urinary, bowel, and sexual domain scores at baseline and three years after diagnosis for patients with prostate
cancer and for controls
University of California, Los Angeles prostate cancer index score (mean (standard deviation))
Active
surveillance
(n=200)
Nerve sparing
RP (n=494)
Non-nerve
sparing RP
(n=476)
EBRT
(n=123)
ADT
(n=61)
Combined
EBRT/ADT
(n=166)
LDR
brachytherapy
(n=58)
HDR
brachytherapy
(n=47)
Controls
(n=495)
Physical component score (normalised to mean of 50 and SD of 10; higher scores indicate better function)
Baseline 47.7 (10.8) 52.3 (7.6) 50.6 (8.7) 49.3 (9.9) 44.2 (10.6) 46.7 (11.3) 52.6 (7.9) 51.4 (8.5) 49.4 (9.6)
3 years 46.9 (11.9) 50.1 (9.0) 48.7 (9.5) 46.5 (10) 38.8 (12.7) 44.1 (11.7) 49 (9.6) 48.5 (11.2) 47.9
Mental component score (normalised to mean of 50 and SD of 10; higher scores indicate better function)
Baseline 51.4 (9.5) 53.6 (7.7) 54.4 (7.4) 53.1 (9.0) 53.4 (8.8) 53.5 (8.6) 51.7 (9.9) 52.6 (8.4) 52.5 (9.1)
3 years 53.1 (9.2) 53.3 (8.5) 53.7 (8.5) 52.9 (9.1) 53.2 (9.7) 52.8 (9.7) 54 (7.8) 51.5 (10.0) 54.1
Urinary function (score range 0-100; higher scores indicate better function)
Baseline 85.7 (19.7) 95.6 (10.7) 94.2 (12.4) 92.9 (13.8) 87.5 (19.4) 90.7 (15.1) 96.8 (7.2) 92.9 (13.3) 95.2 (11.8)
3 years 91.6 (14.7) 85.5 (17.0) 83.3 (19.2) 92.6 (15.2) 92.8 (14.1) 89.9 (16.5) 93.5 (14.3) 89.8 (15.3) 95.4
Urinary bother (score range 0-100; higher scores indicate less bother)
Baseline 58.3 (36.4) 80.5 (28.5) 80.6 (28.6) 77.2 (30.2) 59.2 (35.9) 69.9 (35.3) 80.6 (26.9) 83.0 (30.0) 89.2 (22.6)
3 years 84.1 (25.5) 84.8 (23.5) 83.1 (25.3) 81.4 (27.6) 73.4 (34.3) 79.3 (28.5) 84.4 (24.6) 76.7 (29.1) 89.7
Bowel function (score range 0-100; higher scores indicate better function)
Baseline 83.9 (17.9) 89 (12.0) 87.1 (15.7) 86.4 (16.5) 84.7 (17.9) 87 (14.5) 91.8 (9.3) 88.4 (10.5) 88.4 (12.3)
3 years 86.7 (16.4) 88.1 (13.9) 88.5 (12.3) 84.5 (15.8) 82.1 (18.3) 81.8 (19.0) 88.8 (11.5) 87.8 (16.0) 89.8
Bowel bother (score range 0-100; higher scores indicate less bother)
Baseline 84.3 (28.3) 93 (18.4) 90.4 (22.1) 87.6 (25.9) 83.8 (27.2) 88.1 (24.7) 94.4 (14.8) 93.1 (17.8) 89.2 (23.3)
3 years 88.1 (23.2) 90 (20.9) 90.5 (18.7) 79.8 (28.2) 87.2 (23.8) 78.8 (29.0) 91.1 (14.6) 84.3 (28.4) 93.8
Sexual function (score range 0-100; higher scores indicate better function)
Baseline 61.0 (24.8) 71.8 (21.7) 63.3 (26.8) 57.4 (28.0) 45.0 (31.9) 50.6 (28.6) 69.8 (25.2) 66.3 (23.5) 66.0 (25.7)
3 years 44.1 (29) 34.7 (27.7) 22 (23.6) 32.0 (29.0) 8.3 (16.6) 22.1 (25.9) 54.0 (25.7) 30.3 (32.4) 57.1
Sexual bother (score range 0-100; higher scores indicate less bother)
Baseline 67.0 (37.2) 78.9 (32) 71.1 (36.5) 74.6 (33.5) 64.8 (40.0) 65.1 (37.9) 81.9 (29.5) 70.2 (36.4) 75.3 (34.0)
3 years 65.9 (37.9) 52.2 (39.7) 53.6 (42.2) 57.6 (41.9) 66.5 (44.0) 58.4 (42.2) 66.8 (32.7) 60.5 (37.9) 78.5
Scores not adjusted for differences in demographic or clinical characteristics. Three year means for controls were extrapolated using two and five year data; standard deviations for year
three controls were not estimated.
Abbreviations: ADT, androgen deprivation therapy; EBRT, external beam radiotherapy; HDR, high dose rate; LDR, low dose rate; RP, radical prostatectomy; SD, standard deviation.
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obtain an erection firm enough for sexual intercourse
(table 3). At three years, 67.9% (307/494) of men who
had nerve sparing radical prostatectomy, 86.7% (379/
476) of men who had non-nerve sparing radical pros-
tatectomy, 67.9% (72/123) of men who had external
beam radiotherapy, and 36.4% (20/58) of men who
had low dose rate brachytherapy were impotent.
After adjusting for age, baseline function, income,
areaofresidence,andcomorbidityscore,alltreatment
groupshadworse sexualfunctionthancontrolsatone,
two,andthreeyears(fig4),althoughinallgroupsthere
was some improvement between the score at one year
and that at three years. The treatment with greatest
adverseimpactonsexualfunctionwasandrogendepri-
vation therapy (OR 0.02, 95% CI 0.01 to 0.07). Cases
who had nerve sparing radical prostatectomy had a
better outcome at three years (adjusted OR 0.10, 95%
CI0.08to0.13)thanthosewhohadnon-nervesparing
surgery (adjusted OR 0.05, 95% CI 0.04 to 0.07;
P<0.001).
All treatment groups, with the exception of men on
androgen deprivation therapy (who had poor baseline
function), persistently reported more sexual bother
than controls (fig 4). At three years, 494 men (33% of
cases) reported that they had used some form of treat-
ment to achieve an erection. Use of such treatments
washighestincaseswithgoodbaselinesexualfunction
and, therefore, considerable motivation to return to
baseline function. Of the men who reported seeking
assistance for erectile function, 383 (77.5%) stated
that they used a phosphodiesterase type 5 inhibitor
(forexample,sildenafil,tadalafil,orvardenafil(Viagra,
Cialis, and Levitra, respectively)), although 168
(43.9%) of these individuals stated that such agents
were of “little or no use.” After adjusting for age, base-
linepotency,andtreatmenttype,useofaphosphodies-
terase type 5 inhibitor appeared to have no effect on
potency at three years.
DISCUSSION
We have shown in a representative sample of reason-
ably young men that treatment for early prostate can-
cer has important and persistent adverse effects on
qualityoflife.Theadverseeffectsoftreatmentforpros-
tatecancer tendedto be mostpronouncedin menwho
underwent radical prostatectomy, external beam
radiotherapy, or any treatment involving androgen
deprivation. Only men who had primary androgen
deprivation therapy had poorer general physical or
mental quality of life than controls at three years.
Treatment for prostate cancer caused urinary pro-
blems in the majority of treatment groups, which
became less notable over time. Men who had radical
prostatectomycontinuedtohave poorurinaryfunction
three years after diagnosis. It is importantto note, how-
ever, that men with prostate cancer had worse urinary
function than controls at baseline. Poor bowel function
wasapersistentproblemformenwhoreceivedexternal
beamradiotherapytogetherwithandrogendeprivation
therapy,andallmenwhounderwenttreatmentforpros-
tate cancer reported bowel bother.
Decreased sexual function was the most prevalent
reduction in quality of life three years after diagnosis
of localised prostate cancer. After adjustment for con-
founders, all active treatment groups had significantly
loweroddsofbettersexualfunctionthancontrols,with
some variation by type of treatment.
For each of the three quality of life domains specific
toprostatecancer,acomparisonofthedegreeoflossof
function following treatment with the “bothersome-
ness” of the change in function is of interest. For the
groupwhohadradicalprostatectomy,urinaryandsex-
ualfunctionandbotherscoresweresignificantlybelow
those of controls after treatment; however, bother did
notseemtobeasgreataproblemasimpairedfunction.
Although 12% of men who had prostatectomy
reported prolonged incontinence, an improvement
from 16% at year one, at three years less than 50% of
them considered it any more than a “small” problem.
Table 3 |Unadjusted proportion of men with localised prostate cancer who reported incontinence, moderate or severe bowel problems, or impotence at
baseline and three years after diagnosis
Active
surveillance
(n=200) RP (n=981)
Nerve
sparing RP
(n=494)
Non-nerve
sparing RP
(n=476)
EBRT
(n=123)
ADT
(n=61)
Combined
EBRT/ADT
(n=166)
LDR
brachyther-
apy (n=58)
HDR
brachyther-
apy (n=47)
Controls
(n=495)
Urinary incontinence (n (%))*
Baseline 12 (6.0) 11 (1.1) 3 (0.6) 7 (1.5) 0 (0.0) 4 (6.6) 5 (3.0) 0 (0.0) 0 (0.0) 5 (1.0)
3 years 6 (3.4) 111 (12.3) 43 (9.4) 66 (15.1) 3 (2.7) 2 (4.3) 6 (3.9) 3 (5.4) 3 (7.0) —
Moderate or severe bowel problems (n (%))† †
Baseline 27 (13.5) 43 (4.4) 18 (3.6) 25 (5.3) 13 (10.6) 6 (10.0) 15 (9.0) 0 (0.0) 1 (2.1) 31 (6.3)
3 years 11 (6.3) 32 (3.5) 19 (4.1) 12 (2.7) 16 (14.5) 3 (6.4) 19 (12.5) 0 (0.0) 4 (9.3) —
Impotence (n (%))‡ ‡
Baseline 53 (27.3) 206 (21.5) 76 (15.6) 128 (27.6) 35 (30.2) 24 (42.1) 63 (39.1) 11 (19.0) 12 (25.5) 109 (22.3)
3 years 94 (54.3) 695 (77.4) 307 (67.9) 379 (86.7) 72 (67.9) 45 (97.8) 121 (82.3) 20 (36.4) 31 (72.1) —
Number at baseline includes men with missing data for individual questions (three cases and one control did not answer questions on bowel problems, and 42 cases and six controls did
not answer the question on impotence). Controls were not asked these questions at year three.
*Incontinence defined as needing to wear one or more pad per day to control urinary leakage.
Bowel problems defined as responding to the question “Overall, how big a problem have your bowel habits been?” with either “moderate” or “big.”
‡Impotence defined as being unable to obtain an erection sufficient for sexual intercourse.
Abbreviations: ADT, androgen deprivation therapy; EBRT, external beam radiotherapy; HDR, high dose rate; LDR, low dose rate; RP, radical prostatectomy.
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the active surveillance and androgen deprivation ther-
apy groups, appeared related to the cases’ generally
poor international prostate symptom score (over 30%
reported “severe” symptoms). The majority in these
two groups with severe problems experienced
improvements in urinary bother between baseline
and year one, most likely as a result of transurethral
resection of the prostate or drug treatments for lower
urinary tract symptoms.
Of the cases who reported prolonged impotence
after radical prostatectomy, only 48% described the
disorder as any more than a “small” problem at three
years. Cases who had non-nerve sparing surgery had
worse sexual function than those who had nerve spar-
ing techniques, but were slightly less botheredby their
lossinsexualfunction.Theexpectationsofbetterfunc-
tionafternervesparingsurgerymaypartlyexplainthis
disparity.It is also possiblethat responseshift explains
someorallofthisdifferenceatthreeyears;thatis,indi-
viduals may adapt to a change in health by adjusting
theirinternalstandards,values,orconceptualisationof
quality of life.
15
Interestingly, the health status of men who chose
radical prostatectomy, especially nerve sparing sur-
gery,tendedtobebetterthanthatofmatchedcontrols,
particularlyatbaseline.Menwhochoseradicalprosta-
tectomyweremorelikelytohavebeendiagnosedwith
early stage disease: 47% of those who had surgery had
T1cstageprostatecanceratdiagnosis(generallya can-
cer detected as a result of elevated prostate specific
antigen levels) and 63% reported that their diagnosis
occurred in the absence of symptoms. Men who parti-
cipate in screening are generally healthier than other
men in the population from which they come.
16 A
“healthy screenee” effect can be inferred from the
lowerprevalenceofsmokingamongstudyparticipants
with T1c stage cancer (11.7%) than in all other men
with localised disease (15.1%; P=0.04).
Thisreportpresentsdataonthreeyearqualityoflife
in men diagnosed with localised prostate cancer—that
is,clinicalstagesT1atoT2cwithnoevidenceoflymph
nodeordistantmetastases.Thisrestrictionwasapplied
so that the quality of life comparisons could be made
among men who had a high probability of remaining
disease free during the follow-up period. More
immediateoutcomes,attwoandsixmonthsafterdiag-
nosis, have been described elsewhere.
17 We therefore
concentrated on outcomes to three years after diagno-
sis to allow quality of life to stabilise and thus to reflect
persistent adverse effects of treatment. We achieved
good follow-up rates in most treatment groups: 91%
of all cases interviewed at baseline also completed an
interview at three years.
Strengths and limitations of the study
This study has a number of important strengths. Not
only did we measure quality of life outcomes at one,
two, and three years after prostate cancer diagnosis,
we also measured quality of life at baseline and had
control data for comparison. Very few observational
studiesofqualityoflifeinpatientswithprostatecancer
have a control arm.
18
Theabilitytoadjustqualityoflifedatafortheunder-
lying effects of ageing, baseline function, comorbid
conditions, and other important confounders is
another major strength of our study. The population
based sample of men with prostate cancer that we
used and the broad range of centres at which men
received treatment further strengthen our study find-
ings and their relevance to young men with prostate
cancer.
Our studycomprisesoneofthe largest seriesof men
on active surveillance (n=200). As more younger men
with low stage disease are being diagnosed, active sur-
veillance ismorefrequentlybeingpromotedasa man-
agement option.
19 Our cohort also includes
meaningful numbers of men treated with low dose
rate or high dose rate brachytherapy.
Greater surgical experience and higher patient
volumes are associatedwithbetteroutcomesat institu-
tions treatingpatientswithprostatecancer;
20however,
noteverymanwhoisdiagnosedwiththediseasecanbe
offered this level of expertise. Our results realistically
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with localised prostate cancer can expect three years
after being treated.
There are also some important limitations to this
study. Although the study is population based, the
64% participation rate among eligible cases notified
totheNewSouthWalescentralcancerregistrydetracts
fromitsrepresentativeness.Themultistepconsentpro-
cess and the delay in notification of some cases to the
registry accounts for most of the participation loss.
Eight urologists managing the care of 336 men chose
not to participate in the study. These eight had higher
than average patient volumes. Thus, if patient volume
is associated with better outcomes after treatment, it is
possible that we have overestimated the detrimental
effectsoftreatmentonqualityoflifeinthispopulation.
Compared with all patients with prostate cancer
registered during the recruitment period, our cases
did not differ much in age, area of residence, or socio-
economic status. For example, study participants were
alittlelesslikelytobebornoutsideAustraliathanindi-
viduals not included in the study. Controls were
selected from the electoral roll and matched with elec-
tronic listings of residential telephone numbers. In
2003,95% ofAustralianhouseholdshad a landline tel-
ephone connection and 83% had a white pages
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21 Thus, selection bias may have been intro-
duced into the control sample by requiring that they
havealistednumber.Suchabiaswouldbesmall,how-
ever, because sociodemographic and quality of life
variablesforcontrolsatbaselineweregenerallysimilar
to those for cases, implying that the controls were well
matched to cases in most respects.
The participation rate in controls,63% of those both
eligible and contacted, was less than is desirable, and
there were significantly fewer participating controls
aged55-59 years,unmarried, and livingin majorcities
than among those initially approached. To control for
this selection bias and for other personal and disease
characteristics that might affect outcomes (table 1), we
based our inferences about associations of treatment
with outcomes on confounder adjusted odds ratios.
Baseline assessment of quality of life occurred after
primary therapy had begun in a large proportion of
cases. Baseline data were collected a median of three
months after diagnosis, and participants were asked to
recalltheirqualityoflifeinthemonthbeforediagnosis.
Atthisfirstassessment,96%ofmenwhohadandrogen
deprivation therapy, 88% who had radical prostatect-
omy, 75% who had external beam radiotherapy, 40%
who had high dose rate brachytherapy, and 36% who
had low dose rate brachytherapy had received treat-
ment. This delay may have caused bias in the recall
of prediagnosis quality of life in cases.
22
Research suggests, however, that a high percentage
of men accurately recall prediagnosis quality of life up
tosixmonthsafterdiagnosiswhenusingtheUniversity
of California, Los Angeles prostate cancer index,
8
although recall is poor between seven and 36 months
after treatment.
22 We tested for differences in baseline
scores among men who had their initial interview
before or after initiation of treatment and found no
material differences in any of the domains after adjust-
ing for age and comorbid status (results not shown).
We attempted to reduce differential error in the con-
trols’baselineresponsebyaskingthemtorecallquality
of life three months before interview. We think these
sources of error had only a small impact on outcome
assessments,becausereportedbaselinelevelsforover-
all quality of life and urinary, bowel, and sexual func-
tionincasesweregenerallylittledifferentfromthosein
controls (table 2).
Wereporthereonthethreeyearoutcomes.Insome
treatment groups, particularly the active surveillance
group and the intermittent androgen deprivation ther-
apy group, quality of life may fluctuate depending on
the type, timing, and duration of treatment after the
first year. A total of 27 men (14%) who were defined
as receiving active surveillance moved to radical treat-
ment between six months and two years after diagno-
sis, most of whom (n=19) had a radical prostatectomy.
Their urinary and sexual functionscores at three years
resembled those of the radical prostatectomy group.
Generalisability of the results
The people in New South Wales make up approxi-
mately one third of the Australian population and
adequately represent the ethnic, economic, and health
status mix of the whole country. In addition, given
Australia’s largely publicly funded health system,
New South Wales offers quality of care similar to that
inotherpartsofthecountry.Fiveyearrelativesurvival
for cancer patients diagnosed in New South Wales is
generally equal or close to the best reported rate from
other developed countries.
23 In principle, our findings
canbegeneralisedtomeninotherdevelopedcountries
who were treated for localised prostate cancer in the
early 2000s.
The patterns of care described in this cohort reflect
the care given in 2000 to 2003; however, treatment
patterns have changed somewhat since this time,
which may affect the generalisability of our results.
Open prostatectomy is the most common treatment
for early prostate cancer, but new techniques such as
laparoscopic approaches and robot assisted methods
have now become available. The outcomes from
these new approaches, however, have not yet been
well described. Both high dose rate and low dose rate
interstitial brachytherapy have become more popular
treatment choices since 2003, and techniques for deli-
veringexternalbeamradiotherapyhavechanged,with
more widespread use of conformal therapy and image
guidance.
Ourresults,however,willprobablybeforsometime
agoodguidetooutcomesfromopenradicalprostatect-
omyandtheothertherapieswewereabletodocument
in sufficient numbers. Newer therapies cannot be
assumed to produce better outcomes unless demon-
strated to do so by randomised controlled trials
24 or
by follow-up of large, well documented, and represen-
tative patient cohorts.
The results of this study may not be generalisable to
older men with prostate cancer, as age is associated
with both baseline function and comorbidity, which
inturnareindependentlystronglypredictiveofpoorer
outcomes.
25
Comparison with other studies
Althoughtherehavebeenanumberofstudiesonqual-
ityoflifeafterprostatecancer,
2627webelieveoursisthe
first prospective population based study to assess long
term quality of life among men receiving different
treatment options for localised prostate cancer and to
compare quality of life with that of men randomly
selected from the general population.
Onerandomisedtrialhasdirectlycomparedthequal-
ity of life of patients who had surgery (n=189) with that
amongpatientsonactivesurveillance(n=178)
28:80%of
menwhohadsurgerywereimpotentand18%hadmod-
erate to severe urinary leakage five years after surgery
compared with 45% and 2%, respectively, in the active
surveillance group. A recent study of 1201 cases who
underwentprostatectomy,externalbeamradiotherapy,
or brachytherapy and 625 spouses described outcomes
ofa similardirectionand magnitudetoours, andfound
thatchangesinqualityoflifewereassociatedwithover-
all level of satisfaction of care.
17
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tate cancer, as reflected by mental and physical scores
and reported comorbidities, was eventually similar to,
if not slightly better than, that of our controls. Eur-
opean and American studies have similarly shown
that the quality of life in patients with prostate cancer
returns to baseline or exceeds the health status of the
age related population six to twelve months after
diagnosis.
2930
The continence and potency outcomes of some fre-
quently quoted studies appear better than those in our
study; however, this disparity may be because partici-
pants in other studies were drawn exclusively from
large teaching hospitals and centres of excellence.
3132
In addition, overly favourable outcomes in some stu-
dies may be owing, in part, to variation in the defini-
tions of outcomes and methods used across studies. A
recent review identified 112 published definitions of
incontinence and 79 definitions of erectile
dysfunction.
33 Furthermore, when data are collected
by doctors, patients’ reported sexual function can be
overestimated by as much as 30%
34 and urinary func-
tion by 13% to 65%.
35 In our study, independent inter-
viewers collected outcome data directly from the men
by using a validated instrument.
The selection of patients for various treatment
options is likely to be influenced by the characteristics
of the disease, patient, doctor, and healthcare system.
Quality of care for localised prostate cancer and the
way in which care is delivered may differ between
regions and countries, so the differences in outcomes
between treatment types observed in this study may
not reflect, at least quantitatively, differences in out-
comes in, for example, European or American men.
However, our results are similar in a number of
respects to those of other published series from popu-
lation wide samples of men with prostate
cancer.
171836-38 For example, the five year outcomes
for men in the American prostate cancer outcomes
study who had radical prostatectomy or external
beam radiotherapy were similar to those at three
years in our sample.
39
Conclusions and implications
The aim of treatment of any early stage cancer is to
eradicate the malignancy with the smallest possible
impact on quality of life. We have shown in a popula-
tion representative sample of men that treatment for
early prostate cancer has important and persistent
adverse effects on quality of life, particularly in men
who undergo radical prostatectomy, external beam
radiotherapy, or any treatment involving androgen
deprivation. The extent to which these adverse effects
are balanced by reduced risk of recurrence and better
survival will be seen with further follow-up, within the
limits of what can be inferred from an observational
study. Men with prostate cancer and the clinicians
who treat them need to be aware of the effects of treat-
ment on quality of life, and weigh them up against the
patient’s age and the risk of progression of prostate
cancer if untreated in order to make informed deci-
sions about treatment.
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